CDKN2A and glioma: Park et al. [27] demonstrated significant difference in cumulative survival depending on p16 loss in the whole glioma cohort (p < 0.001) and in a Multivariate Cox regression analysis p16 IHC loss was significantly associated with worse survival in IDH-mut gliomas (HR = 2.6, 95%-CI 1.3–5.4, p = 0.008).